1. Overview
  2. All Stocks
  3. Galmed Pharmaceuticals Ltd

Galmed Pharmaceuticals (GLMD.US) Price Target 2026/2027: 1985% Upside – Rating and Stock Analysis

0,58
-0,86%
Analysis framework by , founder of TradeDesk · Data: EODHD, official filings (SEC) · Updated
Price history for Galmed Pharmaceuticals (GLMD.US) – stock price at 0.58 $, August 2026
Galmed Pharmaceuticals stock price – price development 2026. Updated Aug 6, 2026.
Share this analysis:

Galmed Pharmaceuticals Price Target 2026: Analysts See 1,987% Upside

The average price target for Galmed Pharmaceuticals is $12.00. This price target represents the analysts' view of the stock price over the next 12 months. The stock may be undervalued, because the price target is higher than the current price. The stock is 1.986,96% below the target, which can point to potential returns within the next 12 months if the analysts' view proves right. Also consider the stock's valuation ratios such as P/E, P/S and P/B, plus the technical analysis further down the page, for the full picture.

Is Galmed Pharmaceuticals overvalued or undervalued?

Galmed Pharmaceuticals is currently undervalued with a gap of 1987% relative to the price target.


The current price is $0.58, which places Galmed Pharmaceuticals in the undervalued category. The stock is considered undervalued when the price is below $10.80, and overvalued when the price exceeds $13.20.


The fair value range is defined as ±10% of the price target, because price targets are estimates rather than exact values. For Galmed Pharmaceuticals, the fair value range lies between $10.80 and $13.20.


See the full price target analysis for Galmed Pharmaceuticals →

↑ Back to navigation

Analyst Ratings for Galmed Pharmaceuticals stock in 2026: Hold

1 analysts cover Galmed Pharmaceuticals. Analysts are mostly neutral — 100% recommend Hold. The average price target is $12.00, which gives an upside of 1987% from the current price.

Consensus: Hold (3.00/5)
Hold
1 (100%)
Strong Sell Sell Hold Buy Strong Buy
3.00 out of 5 based on 1 analysts
↑ Back to navigation

About Galmed Pharmaceuticals – Bioteknologi

Galmed Pharmaceuticals (glmd.us) er et biofarmaceutisk selskab, der fokuserer på at udvikle medicin mod leversygdomme. De driver primært forskning i kliniske faser. Deres hovedprodukt er Aramchol, som de tester i et fase III-studie til behandling af NASH (fedtlever), især hos overvægtige patienter med type II-diabetes. Virksomheden tester også Aramchol i et fase IIa-forsøg, der ser på HIV-relateret fedtlever. Galmed Pharmaceuticals arbejder desuden med at udvikle Amilo-5MER, et syntetisk peptid. De har et samarbejde med Gannex Pharma om at udvikle en kombinationsbehandling mod NASH, som kombinerer ASC41 og Aramchol. Virksomheden investerer altså i flere spor for at tackle alvorlige leversygdomme. Read more about the company

Key Figures for Galmed Pharmaceuticals

$ 4,8M Market cap
- Revenue
Bioteknologi Industry
- P/E
61.38 P/S
0.36 P/B
USA Listed on exchange
galmedpharma.com Website
Sundhed Sector

What kind of stock is Galmed Pharmaceuticals?

Speculative stock

Galmed Pharmaceuticals is classified as a speculative stock.

Score Overview for Galmed Pharmaceuticals

💰 Value Score 31/100 (Low)
⭐ Quality Score 9/100 (Very Low)
🚀 Momentum Score 7/100 (Very Low)
📊 Total Score 15/100

⚠️ 3 red flags identified 2 critical

Our analysis has identified 3 potential risk factors in Galmed Pharmaceuticals that investors should be aware of.

⚠️ Weak financial health: The Piotroski score is only 2/9 – the company shows signs of weakened profitability, liquidity or capital structure.
🚨 Weak balance sheet (elevated risk): Altman Z2 is -33.74 – the balance sheet is measurably weaker than average. This is a risk signal based on the numbers, not a bankruptcy prediction.
🚨 Negative return on equity: ROE is -72.1% – the company is generating a negative return for shareholders.

📈 Valuation

The P/S ratio is 61.4 (high — the market pays a premium for the revenue). The P/B ratio is 0.4, below book value, which can point to a value opportunity.

🏦 Financial Health

The Piotroski score is 2 out of 9 — weak financial health, be careful. Altman Z2 is -33.74 (weak balance sheet — elevated risk). The debt-to-equity ratio (D/E) is 13.3% — low debt, a solid balance sheet.

🚀 Momentum & Short Interest

Short interest is 0.40% — low, the market does not expect a decline.

↑ Back to navigation

When Does Galmed Pharmaceuticals Report Earnings – Next Date: 8/27/2026

The next earnings report from Galmed Pharmaceuticals is scheduled for August 27, 2026. This report covers the second quarter (Q2), which ended on June 30, 2026.



↑ Back to navigation

Technical Analysis of Galmed Pharmaceuticals 2026 – Signal: Sell

Overall Technical Signal: Sell

Based on trend analysis (SMA50/SMA200) and MACD trend (positive/negative on a daily + weekly basis). Updated August 6, 2026.

Technical analysis of Galmed Pharmaceuticals (GLMD.US) – RSI 53, MACD positive (bullish), daily candlestick chart August 2026
Galmed Pharmaceuticals technical analysis – candlestick chart with RSI and MACD. Updated Aug 6, 2026.

Trend Analysis of Galmed Pharmaceuticals Ltd

Galmed Pharmaceuticals Ltd is in a short-term uptrend. The price of $0.58 is 5.6% above the 20-day average ($0.55). Medium term, the picture is negative: the price is 0.9% below the 50-day average ($0.59). Long term, the stock is 22.8% below the 200-day average ($0.75), which signals a long-term downtrend.

Death Cross: The 50-day average (0.59) is below the 200-day average (0.75), which is a classic bearish signal for Galmed Pharmaceuticals Ltd.

Is Galmed Pharmaceuticals Ltd overbought or oversold?

Galmed Pharmaceuticals Ltd has an RSI of 52.7, right in the middle of the neutral zone. There is no clear buying or selling pressure.

MACD Analysis for Galmed Pharmaceuticals Ltd

Daily MACD: MACD is positive (0.003), which means the short-term trend is bullish (the 12-day EMA is above the 26-day EMA). MACD is above the signal line (-0.006) by 0.009, which confirms rising momentum in the uptrend.

Weekly MACD: MACD5 is negative (-0.094), which indicates a broader bearish long-term trend. MACD5 is above the signal line (-0.117) by 0.023, which suggests the negative long-term momentum is fading – a bigger trend reversal could be ahead.

Overall MACD assessment: The daily and weekly MACD give conflicting signals. The short-term trend is bullish, but the long-term trend is still bearish. Weekly momentum is rising, though, which could signal an upcoming trend reversal.

Risk Profile for Galmed Pharmaceuticals Ltd

Galmed Pharmaceuticals Ltd has an annual standard deviation of 91.5%, which classifies the stock as extreme risk. Only risk-tolerant investors should consider this stock, because the price swings can be very large.

Overall Technical Conclusion for Galmed Pharmaceuticals Ltd

Trend: Negative. The price trades below SMA50 and SMA200.

MACD trend (zero line): Daily bullish (0.003). Weekly bearish (-0.094).

MACD momentum (signal): Daily rising. Weekly rising.

RSI: 52.7 – neutral.

Technical signal: Sell

The trend is negative and MACD is below the zero line, which confirms the bearish momentum. Consider reducing the position or setting a stop-loss.

↑ Back to navigation

Frequently Asked Questions About Galmed Pharmaceuticals stock in 2026

Should you buy Galmed Pharmaceuticals stock now?
No, the technical signal for Galmed Pharmaceuticals is currently SELL. Galmed Pharmaceuticals trades at $0.58 as of 8/6/2026. The overall technical signal is: Sell. The technical analysis shows the following: MACD is positive (bullish trend) at 0.003 with rising momentum (signal: -0.006); RSI is at 52.7 (neutral zone); the stock is in a short-term uptrend (price above the 20-day average); the analyst price target of $12.00 points to 1,987.0% upside. The stock is in a broader downtrend (below SMA50/SMA200). Buying in a downtrend is generally not recommended. This is a technical observation based on current data, not investment advice.
What is the price target for Galmed Pharmaceuticals stock?
The average analyst price target for Galmed Pharmaceuticals is $12.00. The current price is $0.58, which gives an upside of 1,987.0%. Based on this, the stock is considered undervalued. The fair value range (±10% of the price target) is between $10.80 and $13.20.
Is Galmed Pharmaceuticals a dividend stock?
No, Galmed Pharmaceuticals does not currently pay a dividend to shareholders. The company reinvests its profits in growth instead of paying dividends.
What is the risk of Galmed Pharmaceuticals stock?
Galmed Pharmaceuticals is rated as a stock with extreme risk. the annual standard deviation is 91.5%, which classifies the stock as extreme risk.
Is Galmed Pharmaceuticals overvalued?
No, Galmed Pharmaceuticals is considered undervalued based on the analyst price target (1,987.0% upside). Galmed Pharmaceuticals has the following valuation ratios: a P/S ratio of 61.4, a P/B ratio of 0.4. The analyst price target suggests that the stock is undervalued by 1,987.0%.
Is Galmed Pharmaceuticals overbought?
No, Galmed Pharmaceuticals is not overbought. RSI is at 52.7 (neutral zone). The technical indicators show: RSI is at 52.7 (neutral zone between 30-70), which signals neither overbought nor oversold. In addition, the price is 4.7% above the 20-day average (short-term uptrend). In addition, MACD is positive with rising momentum (bullish).
When is the next Galmed Pharmaceuticals earnings report?
Galmed Pharmaceuticals reports its next earnings on August 27, 2026. The stock currently trades at $0.58.
Is Galmed Pharmaceuticals shorted?
Galmed Pharmaceuticals has minimal short interest of 0.40% of the free float, which is insignificant and points to very limited bearish sentiment.
Are insiders buying Galmed Pharmaceuticals stock?
There is currently no registered insider trading for Galmed Pharmaceuticals.
Is Galmed Pharmaceuticals a good stock?
Based on our total score, Galmed Pharmaceuticals is rated as a disastrous stock with a total score of 16 out of 100. The stock scores very low on value, quality and momentum – it is among the worst in our database. The score is made up of Value: 31/100, Quality: 9/100, Momentum: 7/100. In addition: analysts see 1,987.0% upside to the price target; technical signal: Sell. Whether Galmed Pharmaceuticals is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Galmed Pharmaceuticals stock?
The outlook for Galmed Pharmaceuticals based on current data: the average analyst price target is $12.00 (+1,987.0%); the stock is in a downtrend (below SMA50 and SMA200); the next earnings report is due on 8/27/2026, which can move the price. Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Galmed Pharmaceuticals stock rising?
Galmed Pharmaceuticals is rising right now. The technical indicators show: the price is 4.7% above the 20-day average; MACD is positive with rising momentum (bullish signal). For the latest context, see our technical analysis, insider section and news overview above.
How high can Galmed Pharmaceuticals go?
The average analyst price target for Galmed Pharmaceuticals is $12.00, which corresponds to a potential gain of 1,987.0% from the current price of $0.58. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Galmed Pharmaceuticals fall?
We lack enough history to give a specific floor for Galmed Pharmaceuticals. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Galmed Pharmaceuticals do?
Galmed Pharmaceuticals (glmd.us) er et biofarmaceutisk selskab, der fokuserer på at udvikle medicin mod leversygdomme. De driver primært forskning i kliniske faser. Deres hovedprodukt er Aramchol, som de tester i et fase III-studie til behandling af NASH (fedtlever), især hos ... The company belongs to the Sundhed sector, more specifically the Bioteknologi industry, is headquartered in USA, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Galmed Pharmaceuticals as an investment.
Did Galmed Pharmaceuticals raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Galmed Pharmaceuticals. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history and the news overview above.
Is Galmed Pharmaceuticals making money or losing money?
We have no current profitability data for Galmed Pharmaceuticals. See the latest report in the earnings history above.
Can Galmed Pharmaceuticals go bankrupt?
The bankruptcy risk of Galmed Pharmaceuticals is rated as elevated. Altman Z2 (a model for assessing financial distress) is -33.74 — that places the company in the weak zone. This is a probability based on the numbers, not a verdict — bankruptcy is not imminent. But the balance sheet is measurably weaker than average, so watch the debt, liquidity and possible capital raises. The Piotroski score (financial health 0-9, higher is better) is 2 — which is weak. Debt relative to equity is 13% (low). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Galmed Pharmaceuticals have a lot of debt?
No, Galmed Pharmaceuticals has low debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 13%. For the sundhed sector, anything below 80% counts as low debt. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector.
↑ Back to navigation

Explore More